Sonar circumferential flow conditioner
    1.
    发明授权
    Sonar circumferential flow conditioner 有权
    声纳周向流动调节器

    公开(公告)号:US07926360B2

    公开(公告)日:2011-04-19

    申请号:US12573723

    申请日:2009-10-05

    IPC分类号: G01F1/00

    CPC分类号: G01F1/708 G01F1/74

    摘要: Methods and apparatus enable measuring flow of a fluid within a conduit. For example, flowmeters may measure the velocity of production fluid flowing through production pipe of an oil/gas well. The flowmeters rely on detection of pressure variations generated as a result of a backward-facing step as a basis for flow measurement calculations. Pressure sensing occurs away from the step in a direction of the flow of the fluid in an enhanced turbulence region of the flowmeter where the inner diameter remains enlarged as a result of the step.

    摘要翻译: 方法和装置能够测量导管内流体的流动。 例如,流量计可以测量流过油/气井的生产管道的生产流体的速度。 流量计依赖于作为流量测量计算的基础的后向步骤的结果产生的压力变化的检测。 在步进的结果是内径保持扩大的流量计的增强湍流区域中的流体的流动方向上的压力感测发生在离开台阶的位置。

    Sonar circumferential flow conditioner
    2.
    发明授权
    Sonar circumferential flow conditioner 有权
    声纳周向流动调节器

    公开(公告)号:US07607361B2

    公开(公告)日:2009-10-27

    申请号:US12035578

    申请日:2008-02-22

    IPC分类号: G01F1/42

    CPC分类号: G01F1/708 G01F1/74

    摘要: Methods and apparatus enable measuring flow of a fluid within a conduit. For example, flowmeters may measure the velocity of production fluid flowing through production pipe of an oil/gas well. The flowmeters rely on detection of pressure variations generated as a result of a backward-facing step as a basis for flow measurement calculations. Pressure sensing occurs away from the step in a direction of the flow of the fluid in an enhanced turbulence region of the flowmeter where the inner diameter remains enlarged as a result of the step.

    摘要翻译: 方法和装置能够测量导管内流体的流动。 例如,流量计可以测量流过油/气井的生产管道的生产流体的速度。 流量计依赖于作为流量测量计算的基础的后向步骤的结果产生的压力变化的检测。 在步进的结果是内径保持扩大的流量计的增强湍流区域中的流体的流动方向上的压力感测远离步进。

    Methods and compositions for antibody therapy
    4.
    发明授权
    Methods and compositions for antibody therapy 有权
    用于抗体治疗的方法和组合物

    公开(公告)号:US08592149B2

    公开(公告)日:2013-11-26

    申请号:US12298661

    申请日:2007-04-27

    IPC分类号: C12Q1/68 G01N33/50

    摘要: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a FcγRIIA polymorphism, or a FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and a FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism.

    摘要翻译: 提供了用于确定受试者对抗体治疗的反应性的方法和材料,以及用于基于FcγRIIA多态性或FcγRIIIA多态性或FcgammaRIIA多态性和FcγRIIIA多态性选择和/或治疗受试者 多态性,包括治疗是治疗的地方,如利妥昔单抗。 还提供了用于设计,制备,筛选,测试和/或施用抗体以及基于受试者的FcγRIIA多态性或FcgammaRIIIA多态性或者FcγRIIA多态性和FcγRIIIA多态性两者来优化抗体疗法的方法和材料。

    MULTIPHASE FLOW METER FOR SUBSEA APPLICATIONS USING HYDRATE INHIBITOR MEASUREMENT
    7.
    发明申请
    MULTIPHASE FLOW METER FOR SUBSEA APPLICATIONS USING HYDRATE INHIBITOR MEASUREMENT 有权
    多相流量计用于使用水合物抑制剂测量的SUBSEA应用

    公开(公告)号:US20120046870A1

    公开(公告)日:2012-02-23

    申请号:US12860720

    申请日:2010-08-20

    IPC分类号: E21B47/10 G01F1/74

    摘要: Methods and apparatus for determining phase fractions (relative concentrations) within a multiphase fluid mixture, in the presence of an injected hydrate inhibitor. Combining this phase fraction information with a hydrate inhibitor injection rate (HIIR) enables resolving oil and water flow rates for the phase fractions. The liquid flow rates and a total combined flow rate of the fluid mixture—determined based on a differential pressure of the fluid mixture through a given area—enable resolving a gas flow rate.

    摘要翻译: 在注入的水合物抑制剂存在下,确定多相流体混合物内的相分数(相对浓度)的方法和装置。 将该相分数信息与水合物抑制剂注入速率(HIIR)组合使得能够分解相分数的油和水流速。 基于流体混合物的压差确定的流体混合物的液体流速和总的组合流速,通过给定的面积来确定气体流速。

    METHODS AND COMPOSITIONS FOR ANTIBODY THERAPY
    8.
    发明申请
    METHODS AND COMPOSITIONS FOR ANTIBODY THERAPY 审中-公开
    抗体治疗方法和组合物

    公开(公告)号:US20120039871A1

    公开(公告)日:2012-02-16

    申请号:US12742066

    申请日:2008-11-07

    摘要: Methods and materials are provided for selecting and/or treating a subject based on a FcγRIIA polymorphism, or a FcγRIIB polymorphism, or both an FcγRIIA polymorphism and a FcγRIIB polymorphism, for treatment with a therapy including an antibody therapy such as rituximab. Methods are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIB polymorphism, or both the FcγRIIA polymorphism and the FcγRIIB polymorphism.

    摘要翻译: 提供了用于基于FcγRIIA多态性或FcγRIIB多态性或FcγRIIA多态性和FcγRIIB多态性选择和/或治疗受试者的方法和材料,用于包括抗体治疗如利妥昔单抗的治疗。 还提供了用于设计,制备,筛选,测试和/或施用抗体以及基于受试者的FcγRIIA多态性或FcγRIIB多态性或FcγRIIA多态性和FcγRIIB多态性两者优化抗体疗法的方法。

    METHODS AND COMPOSITIONS FOR ANTIBODY THERAPY
    10.
    发明申请
    METHODS AND COMPOSITIONS FOR ANTIBODY THERAPY 有权
    抗体治疗方法和组合物

    公开(公告)号:US20100291549A1

    公开(公告)日:2010-11-18

    申请号:US12298661

    申请日:2007-04-27

    IPC分类号: C12Q1/68

    摘要: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a FcγRIIA polymorphism, or a FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and a FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism.

    摘要翻译: 提供了用于确定受试者对治疗如抗体疗法的反应性的方法和材料,以及用于基于FcγRIIA多态性或FcγRIIA多态性选择和/或治疗受试者,或者FcγRIIA多态性和FcγRIIIA两者 多态性,包括治疗是治疗的地方,如利妥昔单抗。 还提供了用于设计,制备,筛选,测试和/或施用抗体以及基于受试者的FcγRIIA多态性或FcγRIIIA多态性或FcγRIIA多态性和FcγRIIIA多态性两者优化抗体疗法的方法和材料。